NEXGEN-PD

点击翻译按钮获取中文摘要

Parkinson’s Disease (PD) is a major neurodegenerative disorder with no established treatment modalities capable of modifying diseasepathology, and no means of early diagnosis. Vaccines targeting aSyn aggregates are a promising route to disease-modifying therapyfor PD, but the current generation of PD vaccines utilise conventional formulations, which are limited in their immunogenicity andrequire substantial quantities of adjuvant to achieve efficacy. NEXGEN’s proprietary WISIT vaccine platform is the first of the novelclass of gluconeoconjugate vaccines (GNCVs), which are administered intradermally and specifically formulated to leverage skindendritic cells (DCs) to generate substantially stronger and more specific immune responses than conventional vaccines. These strongerimmune responses allow substantial reduction in adjuvants, while simultaneously increasing therapy efficacy. NEXGEN will identify andcharacterise candidate WISIT constructs targeting aSyn (PD-WISITs) and develop a novel extracellular vesicle (EV)-based biomarkerassay that enables early diagnosis of PD using liquid biopsies, suitable for point of care use. Safety and efficacy of PD-WISITs will bedemonstrated preclinically, before being translated to first-in-human Phase I/Ib clinical trials, along with the novel EV-based biomarkerassay. The results of NEXGEN will be the extraordinary accomplishments of cheap and effective disease-modifying treatment of earlyPD and a novel biomarker assay to diagnose and guide prodromal/early PD treatment. Further still, GNCV technology will be clinicallydemonstrated, which hasthe potential to be transformative to the treatment of a wide range of additional diseases, resulting in far-reachingimpacts to the health of millions.